Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 4,168 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Clear all
Completed Phase 2 Interventional

Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors

NCT00962494
View directory record Official record
Conditions
Blood Cancer, Breast Cancer, Prostatic Neoplasms, Colorectal Neoplasms, Neoplasms
Interventions
Cancer: Thriving and Surviving Online Workshop
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
19 Years and older
Enrollment
585 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy

NCT00582556
View directory record Official record
Conditions
Prostate Cancer
Interventions
Zometa
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies

NCT04158245
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
18F-fluciclovine PET Scan
Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 18 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetic Study of Genistein, a Tyrosine Kinase Inhibitor

NCT00001696
View directory record Official record
Conditions
Cancer
Interventions
Genistein
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 5:34 AM EDT
Active, not recruiting Not applicable Interventional

Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA

NCT03234556
View directory record Official record
Conditions
Health Status Unknown, Elevated PSA
Interventions
Biopsy of Prostate, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, MRI Ultrasound Fusion Guided Biopsy
Procedure · Other · Diagnostic Test
Lead sponsor
University of Southern California
Other
Eligibility
40 Years and older · Male only
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 21, 2026, 5:34 AM EDT
Completed No phase listed Observational

Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data

NCT00341939
View directory record Official record
Conditions
Prostate Cancer, Breast Cancer, Cutaneous T-Cell Lymphoma, Lung Cancer, Melanoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 21, 2026, 5:34 AM EDT
Terminated Early Phase 1 Interventional

Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance

NCT02421575
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Hydroxychloroquine, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 21, 2026, 5:34 AM EDT
Recruiting No phase listed Observational

Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL

NCT05588128
View directory record Official record
Conditions
Prostate Cancer, Biochemically Recurrent
Interventions
18F-DCFpyL
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Not applicable Interventional Results available

Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer

NCT02489357
View directory record Official record
Conditions
Stage IV Prostate Cancer
Interventions
Cryosurgery, Degarelix, Laboratory Biomarker Analysis, Pembrolizumab
Procedure · Drug · Other + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 12, 2021 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Phase 1Phase 2 Interventional

Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer

NCT03888612
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
ARV-110
Drug
Lead sponsor
Arvinas Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
54
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 51 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer

NCT02643667
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ibrutinib, Radical prostatectomy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
San Francisco, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Phase 1 Interventional Results available

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

NCT03840200
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Ovarian Cancer
Interventions
Ipatasertib, Rucaparib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
San Marcos, California • East Brunswick, New Jersey • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 21, 2026, 5:34 AM EDT
Not listed Phase 3 Interventional Results available

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

NCT01949337
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
enzalutamide, abiraterone, prednisone
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
1,311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
527
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 382 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 21, 2026, 5:34 AM EDT
Recruiting Phase 2 Interventional

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

NCT06632977
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Genetic testing, Valemetostat Tosylate, Magnetic Resonance Imaging, Computed Tomography, Bone scan, FDG-Positron Emission Tomography, PSMA PET Scan, Biospecimen Collection, Carboplatin, Cabazitaxel, Abiraterone Acetate, Enzalutamide, Lutetium Lu 177 Vipivotide Tetraxetan
Other · Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
108
States / cities
Birmingham, Alabama • Tucson, Arizona • Chico, California + 91 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)

NCT00313781
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
CP-751,871, docetaxel, prednisone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
6
States / cities
Los Angeles, California • New York, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Not applicable Interventional

A Study Of the Effectiveness Of Pomegranate Pills in Men With Prostate Cancer Before Prostatectomy

NCT00719030
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pomegranate pill, Pomegranate pill placebo
Dietary Supplement
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 21, 2026, 5:34 AM EDT
Recruiting Phase 1Phase 2 Interventional

NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial

NCT06066437
View directory record Official record
Conditions
Prostate Cancer
Interventions
Arm A: 177Lu rhPSMA-10.1, Arm B: 177Lu rhPSMA-10.1 plus Degarelix
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Vitamin D and Prostate Cancer: A Clinical Study Enrolling Subjects Undergoing Prostatectomy

NCT02726113
View directory record Official record
Conditions
Prostate Cancer
Interventions
cholecalciferol, placebo
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
19 Years to 90 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer

NCT00064610
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
VELCADE TM (bortezomib) for Injection
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2008 · Synced Oct 21, 2026, 5:34 AM EDT
Withdrawn Not applicable Interventional

Health Interventions in Men Undergoing Radical Prostatectomy

NCT01748110
View directory record Official record
Conditions
Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy, Urinary Incontinence
Interventions
Intensive Fitness Intervention, TRIMM
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 65 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Phase 2 Interventional

Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

NCT02445976
View directory record Official record
Conditions
Prostate Cancer
Interventions
Seviteronel: given orally once daily in 28-day cycles
Drug
Lead sponsor
Innocrin Pharmaceutical
Industry
Eligibility
18 Years and older · Male only
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Phase 2 Interventional

Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer

NCT00258284
View directory record Official record
Conditions
Prostate Cancer
Interventions
capecitabine, docetaxel
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 21, 2026, 5:34 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Oral MRT-2359 in Selected Cancer Patients

NCT05546268
View directory record Official record
Conditions
NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL, L-MYC and N-MYC Amplified Solid Tumors, NSCLC With High or Low L-MYC or N-MYC Expression, HR-positive, HER2-negative Breast Cancer, Prostate Cancer
Interventions
Oral MRT-2359
Drug
Lead sponsor
Monte Rosa Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 21, 2026, 5:34 AM EDT
Completed Not applicable Interventional Results available

The Safety and Effectiveness of UroLift: LIFT Pivotal Study

NCT01294150
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
UroLift System, Cystoscopy, Crossover
Device · Other
Lead sponsor
NeoTract, Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
San Diego, California • San Jose, California • Englewood, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 21, 2026, 5:34 AM EDT